Biogen's Al Sandrock says the FDA needs to approve their controversial Alzheimer's drug — now
Al Sandrock is an outspoken champion for aducanumab. And he clearly believes that the FDA needs to approve it now — overriding the controversy it’s sparked — or face criticism from patients clamoring for some kind of medication to slow the disease.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.